NeuroPace, Inc. (NASDAQ:NPCE) Insider Martha Morrell Sells 3,200 Shares

NeuroPace, Inc. (NASDAQ:NPCE) insider Martha Morrell sold 3,200 shares of the business’s stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $15.01, for a total transaction of $48,032.00. Following the completion of the transaction, the insider now owns 87,062 shares of the company’s stock, valued at $1,306,800.62. The trade was a 3.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

NeuroPace Price Performance

NPCE stock opened at $14.19 on Friday. NeuroPace, Inc. has a 1 year low of $5.45 and a 1 year high of $18.15. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. The stock has a market cap of $423.57 million, a price-to-earnings ratio of -14.19 and a beta of 2.02. The company has a 50 day simple moving average of $11.75 and a 200 day simple moving average of $8.81.

NeuroPace (NASDAQ:NPCE) last posted its earnings results on Tuesday, November 12th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The firm had revenue of $21.06 million for the quarter, compared to analyst estimates of $19.33 million. During the same period in the previous year, the firm posted ($0.28) EPS. Research analysts anticipate that NeuroPace, Inc. will post -1 EPS for the current fiscal year.

Institutional Investors Weigh In On NeuroPace

Institutional investors have recently added to or reduced their stakes in the business. KCK LTD. bought a new stake in shares of NeuroPace in the 4th quarter valued at $58,981,000. Millennium Management LLC boosted its stake in shares of NeuroPace by 13.3% in the 2nd quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock valued at $5,186,000 after purchasing an additional 80,324 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of NeuroPace by 8.7% in the 3rd quarter. Geode Capital Management LLC now owns 317,192 shares of the company’s stock valued at $2,211,000 after purchasing an additional 25,330 shares during the last quarter. State Street Corp boosted its stake in shares of NeuroPace by 9.1% in the 3rd quarter. State Street Corp now owns 155,490 shares of the company’s stock valued at $1,084,000 after purchasing an additional 12,912 shares during the last quarter. Finally, XTX Topco Ltd boosted its stake in shares of NeuroPace by 56.1% in the 2nd quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock valued at $182,000 after purchasing an additional 8,643 shares during the last quarter. 78.83% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently commented on NPCE. JPMorgan Chase & Co. boosted their target price on shares of NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a research report on Tuesday, December 17th. Wells Fargo & Company boosted their target price on shares of NeuroPace from $13.00 to $17.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, UBS Group assumed coverage on shares of NeuroPace in a research report on Tuesday, January 21st. They set a “buy” rating and a $17.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $14.80.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.